StockIQpro
NASDAQ:SKYE

Skye Bioscience, Inc.

Track all markets on TradingView
Track all markets on TradingView

Skye Bioscience, Inc. reported net income of −$55.9M in fiscal 2025. Free cash flow was −$43.1M, and the diluted share count rose 8.7%.Summary generated from Skye Bioscience, Inc.'s SEC filings. Latest annual report filed Mar 10, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−126.8%
Debt / equityn/a
Free cash flow−$43.1M
FCF marginn/a
Share count change+8.7%

Financials

Fiscal years, $M
Item20212022202320242025
Revenuen/an/an/an/an/a
Operating income−8−18−35−30−58
Net income−9−19−38−27−56
Free cash flow−7−13−14−27−43

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations